BioSpace News Archive

Drug Development

Axsome’s Migraine Drug Provides Relief in Phase III Trial

Axsome Therapeutics reported positive data from the long-term, open-label Phase III MOVEMENT trial of AXS-07 for the treatment of acute migraine.

December 31, 2020
·
2 min read
·
Mark Terry
Business

BioSpace Movers & Shakers, Jan. 1

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

December 31, 2020
·
3 min read
·
Alex Keown
Biotech Bay

New and Emerging Drug Classes That Will Outlast the Pandemic

From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.

December 31, 2020
·
8 min read
·
Heather McKenzie
Madrona Venture Group Nets $500 Million in Oversubscribed Funds

Seattle-based Madrona Venture Group closed $500 million in new funds that will be used to accelerate startup tech and life science companies primarily in the Pacific Northwest.

December 31, 2020
·
2 min read
·
Alex Keown
Deals

Top 2020 Biopharma M&A Deals

BioSpace highlights a number of the key M&A deals struck over the past 12 months.

December 31, 2020
·
5 min read
·
Alex Keown
Drug Development

10 Biopharma Stories to Look Forward to in 2021

If 2020 taught us anything, it was that unexpected things happen. That said, there are some stories we’ll be watching for. Here’s a look.

December 31, 2020
·
9 min read
·
Mark Terry
Policy

AstraZeneca Vaccine Not Likely to Receive U.S. EUA Until April, Warp Speed Chief Says

The U.K authorized AstraZeneca’s COVID-19 vaccine on Wednesday, but it could be April at the earliest before the drug will likely be administered in the United States, Operation Warp Speed’s chief said.

December 31, 2020
·
2 min read
·
Alex Keown
Drug Development

Clinical Catch-Up: December 28, 2020-January 1, 2021

It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.

December 31, 2020
·
5 min read
·
Mark Terry
Business

Therapeutic Solutions International Launches Campbell Neurosciences Inc as First Suicide Focused Regenerative Psychiatry Biotechnology Company

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today the launching of Campbell Neurosciences Inc as a partially owned spin-off from the Company.

December 31, 2020
·
3 min read
Early Multidrug COVID-19 Treatment Can Prevent Hospitalizations and Deaths, States Physicians for Civil Defense

An international collaboration of physicians has just published an updated protocol for early at-home treatment of COVID-19, which recognizes the three stages of the disease

December 31, 2020
·
1 min read